medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2020, Number 2

<< Back Next >>

Rev ADM 2020; 77 (2)

HIV/AIDS associated Kaposi’s sarcoma: importance of its diagnosis for a correct odontologic management

Díaz CGP, Alvarado SA, de la Garza AI, Guerra LDA

Language: Spanish
References: 52
Page: 100-107
PDF size: 258.21 Kb.


ABSTRACT

Kaposi sarcoma (KS) is an uncommon malignant vascular neoplasm, associated with human herpes virus type 8. There are four clinical presentations: classic, endemic, associated with iatrogenic immunosuppression and associated with AIDS. This article presents a review of the literature on epidemiology, pathogenesis, clinical manifestations, treatment and HIV/AIDS-associated Kaposi sarcoma (SK-HIV/AIDS) regarding a clinical case managed at the Academic Center of Dental Care. The decrease in the incidence of this neoplasm, leads to ignorance of its clinical manifestations. In addition, seropositive patients usually don’t mention their condition in the anamnesis, which represents a risk for the patients on their diagnosis and the case management as well as for the dentist and the clinical personnel from risk of infection.


REFERENCES

  1. Feller L, Wood NH, Lemmer J. HIV-associated Kaposi sarcoma: pathogenic mechanisms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104 (4): 521-529.

  2. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet. 1995; 346 (8978): 799-802.

  3. US Department of Health and Human Services. AIDS info Glossary of HIV/AIDS-Related Terms. 2008. Disponible en: https://aidsinfo.nih.gov/contentfiles/glossaryhivrelatedterms_english.pdf

  4. Antmam K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000; 342 (14): 1027-1038.

  5. Cancela RB, Álvarez-Gallegos V. Sarcoma de Kaposi clásico. Rev Cent Dermatol Pascua. 2000; 9 (1): 6-10.

  6. Enríquez AR. Sarcoma de Kaposi?: revisión de la literatura e ilustración de un caso. Acta Médica Grup Ángeles. 2013; 11 (1): 23-31.

  7. Najafi F, Kafaie P, Neamatzadeh H. Treatment of an early Kaposi ’s sarcoma case post kidney transplantation by sirolimus?: a case report. Acta Med Iran. 2016; 55 (2): 139-141.

  8. Lima CT, Araújo PSR, Teixeira HM, Santos JBD, Silveira VMD. Clinical and laboratory characteristics, staging, and outcomes of individuals with AIDS-associated Kaposi’s sarcoma at an university hospital. An Bras Dermatol. 2017; 92 (2): 172-176.

  9. Ficarra G, Berson AM, Silverman S. Kaposi’s sarcoma of the oral cavity?: a study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects, and treatment. Oral Surg. 1988; 66 (5): 543-550.

  10. Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100 (5): 571-578.

  11. Epstein JB. Management of oral Kaposi’s sarcoma and a proposal for clinical staging. Oral Dis. 1997; 3 (1): 124-128.

  12. Fatahzadeh M, Schwartz RA, Edin F. Oral Kaposi’s sarcoma?: a review and update. Int J Dermatol. 2013; 52 (1): 666-672.

  13. Petit JC, Ripamonti U, Hillef J. Progressive changes of Kaposi’s sarcoma of the gingiva and palate. J Periodontol. 1986; 57 (3): 159-163.

  14. Chaurasia A. CD4+ counts and oral lesions in HIV infected/AIDS patients- an Indian perspective. Juniper Online J Case Stud. 2017; 1 (5): 4-7.

  15. Agaimy A, Mueller SK, Harrer T, Bauer S, Thompson LDR. Head and neck Kaposi sarcoma?: clinicopathological analysis of 11 cases. Head Neck Pathol [Internet]. 2018; 12 (4): 511-516. Available from: http://dx.doi.org/10.1007/s12105-018-0902-x

  16. Lausten LL, Ferguson BL, Barker BF, Cobb CM. Case report oral Kaposi sarcoma associated with severe alveolar bone loss?: case report and review of the literature case report. J Periodontol. 2003; 74 (11): 1668-1675.

  17. Kalpidis CDR, Lysitsa SN, Lombardi T, Kolokotronis AE, Antoniades DZ, Samson J. Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related kaposi sarcoma. J Periodontol. 2006; 77 (3): 523-533.

  18. Reichart PA. Oral manifestations in HIV infection: Fungal and bacterial infections, Kaposi’s sarcoma. Med Microbiol Immunol. 2003; 192 (3): 165-169.

  19. Maya A, Segovia S, Madrigal S, Abrego I, Salas-Alanis JC. Sarcoma de Kaposi en región oral y maxilofacial, una neoplasia olvidada. Rev Esp Cir Oral y Maxilofac. 2018; 40 (1): 22-26.

  20. Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma–associated herpesvirus replication to antiviral drugs. Phys Today. 1971; 24 (5): 2082-2086.

  21. Casper C, Krantz EM, Corey L, Kuntz R, Wang J, Selke S et al. Valganciclovir for suppression of human herpesvirus 8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2009; 198 (1): 23-30.

  22. Riva G, Barozzi P, Torelli G, Luppi M. Immunological and inflammatory features of Kaposi’s sarcoma and other Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8-associated neoplasias. AIDS Rev. 2010; 12 (1): 40-51.

  23. Schulz TF. The pleiotropic effects of Kaposi’s sarcoma herpesvirus. J Pathol. 2006; 208 (1): 187-198.

  24. Ariza-heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation. 2011; 92 (8): 837-844.

  25. Heyrman B, Becker A De, Schots R. A case report of immunosuppression? related Kaposi’s sarcoma after autologous stem cell transplantation. BMC Res Notes. 2016; 9 (188): 1-5.

  26. Instituto Nacional del Cáncer. Targa. Diccionario de Cáncer. 2020. p. 1. Disponible en: https://www.cancer.gov/espanol/publicaciones/diccionario/def/targa

  27. By Jmarchn, HIV-drug-classes-es [Figura 2] (https://commons.wikimedia.org/wiki/File:HIV-drug-classes-es.svg), https://creativecommons.org/licenses/by-sa/3.0/legalcode

  28. Pantanowitz L, Khammissa RA, Lemmer J, Feller L. Oral HIV-associated Kaposi sarcoma. J oral Pathol Med. 2013; 42: 201-277.

  29. Feller L, Lemmer J. Oral Kaposi sarcoma. In: Pantanowitz L, Stebbing J, Dezube BJ, eds. Kaposi sarcoma: a model of oncogenesis. Kerala, India: Research Signpost; 2010. pp. 295-303.

  30. Reyes-Corcho A, Bouza-Jiménez Y. Síndrome de reconstitución inmunológica asociado al virus de la inmunodeficiencia humana y sida. Estado del arte. Enferm Infecc Microbiol Clin. 2010; 28 (2): 110-121.

  31. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome?: more answers , more questions. J Antimicrob Chemother. 2018; 57 (1): 167-170.

  32. Stone SF, Price P, French MA. Immune restoration disease: a consequence of dysregulated immune responses after HAART. Curr HIV Res. 2004; 2 (3): 235-242.

  33. Manandhar R, Shrestha N, Butlin CR, Mycobacterial PWR, Leprosy A. High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol. 2002; 128: 333-338.

  34. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004; 38 (8): 1159-1166.

  35. Montoya E, Harold J, Leguízamo E, Nayive D. Manifestaciones orales de la infección por VIH/sida en niños y adolescentes?: aspectos clínicos, epidemiología y pautas de tratamiento. Univ Odontológica. 2011; 30 (64): 37-50.

  36. Schöfer H. Kaposi-sarkom-Update 1997. In: Garbe C, Rassner G (eds.). Dermatologie. Heidelberg: Springer, Berlin; 1998.

  37. Shirlaw PJ, Chikte U, Macphail L, Croser D, Reichart P. Oral and dental care and treatment protocols for the management of HIV-infected patients. Oral Dis. 2002; 8 (2): 136-143.

  38. Tappero JW, Conant MA, Wolfe SF, Berger TG. Continuing medical education Kaposi’s sarcoma. J Am Acad Dermatol [Internet]. 1993; 28 (3): 371-395. Available from: http://dx.doi.org/10.1016/0190-9622(93)70057-Z

  39. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, De la Rosa-García E, Volkow-Fernández P, Súchil-Bernal L et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002; 38 (5): 460-467.

  40. Merino JE, Janina R, Valdez L. Escleroterapia. Rev Cent Dermatol Pascua. 2008; 17 (1): 11-18.

  41. Scully C, Langdon J, Evans J. Marathon of eponyms?: 11 Kaposi sarcoma. Oral Dis. 2010; 16 (1): 402-403.

  42. Pinheiro S, Teno T, Maria C, Ribeiro B, Lea JC, Pomarico I et al. Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. Oral Pathol Med. 2009; 38 (1): 613-622.

  43. Reichart PA. Oral pathology of acquired immunodeficiency syndrome and oro-facial Kaposi’s sarcoma. In: Seifert G (eds.). Oral pathology. Current topics in pathology. Vol 90. Heidelberg: Springer, Berlin; 1996.

  44. Yarchoan R. Therapy for Kaposi’s sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999; 21 Suppl 1: S66-S73.

  45. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother. 1991; 28 Suppl B: 27-38.

  46. Girum T, Wasie A, Worku A. Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in ethiopia: a time series analysis. BMC Infect Dis. 2018; 18 (1): 1-10.

  47. Ortblad KF, Lozano R, Murray CJL. The burden of HIV: Insights from the global burden of disease study 2010. AIDS. 2013; 27 (13): 2003-2017.

  48. Centro Nacional para la Prevención y el Control del VIH y el sida. Vigilancia epidemiológica de casos de VIH/SIDA en México. Registro Nacional de Casos de sida. Actualización al 2019.

  49. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ. 2005; 83 (9): 700-706.

  50. Ottria L, Lauritano D, Oberti L, Candotto V, Cura F, Tagliabue A et al. Prevalence of HIV-related oral manifestations and their association with HAART and CD4+ T cell count: a review. J Biol Regul Homeost Agents. 2018; 32 (2 Suppl. 1): 51-59.

  51. Elizondo JE, Treviño AC, Violant D. Dentistry and HIV/AIDS related stigma. Rev Saude Publica. 2015; 49. pii: S0034-89102015000100263.

  52. Garza AMG. Control de infecciones y bioseguridad en odontología. (2a ed. Ciudad de México: El Manual Moderno; 2016.




2020     |     www.medigraphic.com